Among patients with resectable non-small cell lung cancer, Opdivo plus Yervoy has displayed potential long-term clinical ...

The European Commission (EC) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with the recombinant human monoclonal antibody Yervoy (ipilimumab ...

Perspective, Therapeutics (CATX) announced that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of ...

Opdivo plus Yervoy showed a median overall survival of 23.7 months vs. 20.6 months with lenvatinib or sorafenib in the CheckMate -9DW trial. The overall response rate for Opdivo plus Yervoy was 36 ...

Squibb announced that the European Commission has approved Opdivo plus Yervoy for the first-line treatment of adult ...

Bristol Myers Squibb has bolstered its case for Opdivo to be used as a preoperative treatment for non-small cell lung cancer (NSCLC) as it has delivered an overall survival (OS) edge when added to ...

Opdivo plus chemotherapy showed a significant overall survival benefit in resectable NSCLC, per final Phase 3 CheckMate -816 study results. In October, the FDA approved Opdivo for resectable NSCLC ...

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology ...

On Wednesday, Bristol Myers Squibb & Co (NYSE:BMY) announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 study, which evaluated Opdivo (nivolumab) in combination ...